According to a new report, published by KBV research, The Global Preimplantation Genetics Diagnosis (PGD) Market size is expected to reach $159.8 million by 2028, rising at a Market growth of 9.7% CAGR during the forecast period.
The Chromosomal Abnormalities segment is showcasing a CAGR of 8.9% during (2022 - 2028). This is due to an increase in the number of patients suffering from genetic disorders. In addition, the growth of the segment would further be driven by growing public knowledge of embryo genetic testing. Moreover, the rise in infertility rates and the rise in inherited disorders boosted Market expansion.
Asia Pacific is the fastest growing region in the Global Preimplantation Genetics Diagnosis (PGD) Market by Region in 2021, and would continue to be a dominant Market till 2028; thereby, achieving a Market value of $44.1 million by 2028. The Europe Market is estimated to witness a CAGR of 9% during (2022 - 2028). Additionally, The North America Market would exhibit a CAGR of 8.5% during (2022 - 2028).
Full Report: https://www.kbvresearch.com/preimplantation-genetics-diagnosis-market/
The Market research report has exhaustive quantitative insights providing a clear picture of the Market potential in various segments across the globe with country wise analysis in each discussed region. The key impacting factors of the Market have been discussed in the report with the elaborated company profiles of Illumina, Inc., Invitae Corporation, Natera, Inc., Agilent Technologies, Inc., PerkinElmer, Inc., Quest Diagnostics Incorporated, Reproductive Genetic Innovations, PacGenomics, CeGaT GmbH, and Laboratory Corporation of America Holdings.
By Test Type
By Geography
Companies Profiled
Unique Offerings 
